Current Report Filing (8-k)
June 22 2017 - 04:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2017
PSIVIDA CORP.
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
000-51122
|
|
26-2774444
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
480 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices) (Zip Code)
(617) 926-5000
(Registrants Telephone Number, Including Area Code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 22, 2017, pSivida Corp. issued a press release announcing that the Company
has submitted a Marketing Authorization Application to the European Medicines Agency, seeking approval to market the Companys Durasert three-year treatment for posterior segment uveitis in the European Union. A copy of the press release making
such announcement is filed as Exhibit 99.1 hereto.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release dated June 22, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PSIVIDA CORP.
|
|
|
|
|
Date: June 22, 2017
|
|
|
|
By:
|
|
/s/ Nancy Lurker
|
|
|
|
|
Name:
|
|
Nancy Lurker
|
|
|
|
|
Title:
|
|
President and CEO
|
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2023 to Mar 2024